Deubiquitylating Enzymes in Cancer and Immunity

Author:

Ren Jiang1,Yu Peng2,Liu Sijia34,Li Ran1,Niu Xin5,Chen Yan1,Zhang Zhenyu6,Zhou Fangfang7,Zhang Long1358ORCID

Affiliation:

1. The Eighth Affiliated Hospital Sun Yat‐sen University Shenzhen 518033 P. R. China

2. Zhongshan Institute for Drug Discovery Shanghai Institute of Materia Medica Chinese Academy of Sciences Zhongshan Guangdong P. R. China

3. International Biomed‐X Research Center Second Affiliated Hospital of Zhejiang University School of Medicine Zhejiang University Hangzhou P. R. China

4. Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province Hangzhou 310058 China

5. MOE Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network Life Sciences Institute Zhejiang University Hangzhou 310058 P. R. China

6. Department of Neurosurgery The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450003 P. R. China

7. Institutes of Biology and Medical Science Soochow University Suzhou 215123 P. R. China

8. Cancer Center Zhejiang University Hangzhou Zhejiang 310058 P. R. China

Abstract

AbstractDeubiquitylating enzymes (DUBs) maintain relative homeostasis of the cellular ubiquitome by removing the post‐translational modification ubiquitin moiety from substrates. Numerous DUBs have been demonstrated specificity for cleaving a certain type of ubiquitin linkage or positions within ubiquitin chains. Moreover, several DUBs perform functions through specific protein–protein interactions in a catalytically independent manner, which further expands the versatility and complexity of DUBs’ functions. Dysregulation of DUBs disrupts the dynamic equilibrium of ubiquitome and causes various diseases, especially cancer and immune disorders. This review summarizes the Janus‐faced roles of DUBs in cancer including proteasomal degradation, DNA repair, apoptosis, and tumor metastasis, as well as in immunity involving innate immune receptor signaling and inflammatory and autoimmune disorders. The prospects and challenges for the clinical development of DUB inhibitors are further discussed. The review provides a comprehensive understanding of the multi‐faced roles of DUBs in cancer and immunity.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3